Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI South East AsiaCPhI South East Asia
Not Confirmed
Not Confirmed
16-18 July, 2025
Not Confirmed
Not Confirmed
13-16 July, 2025
Not Confirmed
Not Confirmed
14-15 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
Industry Trade Show
Not Confirmed
13-16 July, 2025
Industry Trade Show
Not Confirmed
14-15 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
20 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/20/2885171/0/en/Aerami-Therapeutics-Presents-New-Lung-Deposition-Modeling-Data-For-AER-901-in-Pulmonary-Hypertension-at-the-American-Thoracic-Society-2024-International-Conference.html
08 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/08/2877813/0/en/Aerami-Therapeutics-to-Present-New-Lung-Deposition-Modeling-Data-for-AER-901-in-Development-for-Pulmonary-Hypertension-at-the-American-Thoracic-Society-2024-International-Conferenc.html
05 Oct 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/10/05/2755336/0/en/Aerami-Therapeutics-to-Present-Data-Supporting-AER-901-Dosing-Regimen-at-CHEST-2023.html
12 Sep 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/09/12/2741811/0/en/Aerami-Therapeutics-Announces-Presentation-of-Phase-1-Clinical-Trial-Data-for-Lead-Program-AER-901-at-the-2023-European-Respiratory-Society-ERS-International-Congress.html
02 Jun 2023
// CONTRACT PHARMA
https://www.contractpharma.com/contents/view_breaking-news/2023-06-02/aerami-therapeutics-expands-management-team/?widget=listSection
01 Jun 2023
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2023/06/01/2680278/0/en/Aerami-Therapeutics-Appoints-Joshua-Ziel-as-COO-and-Interim-CEO-and-Expands-Management-Team-as-Lead-Asset-AER-901-inhaled-imatinib-Advances-Toward-Phase-2-in-Pulmonary-Hypertension.html
Details:
AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: AER-901
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 24, 2023
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.
Product Name : AER-901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2023
Details:
AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: AER-901
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 04, 2023
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.
Product Name : AER-901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 04, 2023
Details:
AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: AER-901
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 23, 2023
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AER-901 (imatinib mesylate) is a tyrosine kinase inhibitor of PDGFR α and β kinases, Abl, DDR, and c-KIT may therefore prove efficacious in the treatment of pulmonary arterial hypertension.
Product Name : AER-901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 23, 2023
Details:
AER-901 is a drug-device combination that is designed to deliver potentially reverse-remodeling therapy with imatinib mesylate deeply and efficiently throughout the diseased tissue of the lung via the FOX® nebulizer.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: AER-901
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 21, 2022
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AER-901 is a drug-device combination that is designed to deliver potentially reverse-remodeling therapy with imatinib mesylate deeply and efficiently throughout the diseased tissue of the lung via the FOX® nebulizer.
Product Name : AER-901
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 21, 2022
Details:
Aerami will undertake its own PAH clinical development program in the US and other territories for AER-901, drug device combination product pursuant to a worldwide license from Vectura Group plc to develop and commercialize imatinib for the treatment of PAH.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: AER-901
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: Hangzhou Chance Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 02, 2021
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Hangzhou Chance Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Aerami will undertake its own PAH clinical development program in the US and other territories for AER-901, drug device combination product pursuant to a worldwide license from Vectura Group plc to develop and commercialize imatinib for the treatment of ...
Product Name : AER-901
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 02, 2021
Details:
Proceeds from the transaction will be applied toward advancing AER-901, Aerami’s proprietary inhaled, nebulized formulation of imatinib into a planned Phase 2/3 clinical trial in 2022.
Lead Product(s): Imatinib Mesylate
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: AER-901
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: FoxWayne Enterprises
Deal Size: $308.0 million Upfront Cash: Undisclosed
Deal Type: Merger July 12, 2021
Lead Product(s) : Imatinib Mesylate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : FoxWayne Enterprises
Deal Size : $308.0 million
Deal Type : Merger
Details : Proceeds from the transaction will be applied toward advancing AER-901, Aerami’s proprietary inhaled, nebulized formulation of imatinib into a planned Phase 2/3 clinical trial in 2022.
Product Name : AER-901
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 12, 2021
ABOUT THIS PAGE